Our results indicate that 15d-PGJ2 targets JAK signalling independent of EGFR signalling and suggest that inhibition of IL-6-mediated JAK signalling and suppression of EGFR-independent Stat3 activation may represent a novel therapeutic approach in oral cancer. The gene discussed is EGFR; the disease is lip and oral cavity carcinoma.